Skip to main content

Table 1 Study characteristics and 1-year outcomes of studies included in the network meta-analysis (HBeAg-positive patients only)

From: The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis

Source Treatment duration Study design Number of patients Treatment Age (years) Male (%) Endpoint timepoint Method used to measure HBV DNA LLOQ Baseline viral load (log10copies/ml) Undetectable HBV DNA at 1 year (%)
018 Study Group [13] 52 weeks Randomised, controlled, open label 45 TBV 600 mg 34 78 52 weeks Amplicor PCR Assay (Roche) 300 copies/ml 9.57 60
44 ADV 10 mg 30 91 9.98 40.9
ADV 437 Study Group [14] 48 weeks Randomised, single blind 167 Placebo 37 71 48 weeks Amplicor PCR Assay (Roche) 400 copies/ml 8.12 0
171 ADV 10 mg 34 76 8.25 21.1
AHLSG [15] 52 weeks Randomised, double blind 72 Placebo 29 72 52 weeks Solution hybridising assay (Abbott) 1.6 pg/ml 1.85 NR
143 LAM 100 mg 31 74 1.8 NR
AI463023 [12] 96 weeks Phase 3 randomised, double blind 225 ETV 0.5 mg - - 52 weeks PCR assay (company unspecified) 300 copies/ml 8.80 73.8
221 LAM 100 mg - - 8.70 37.6
BeHoLD_I [17] 60 weeks Phase 3 randomised, double blind 354 ETV 0.5 mg 35 77 48 weeks Amplicor PCR Assay (Roche) 300 copies/ml 9.62 66.7
355 LAM 100 mg 35 74 9.69 36.3
Globe study group [1921] NR Phase 3 randomised, double blind 463 LAM 100 mg 33 76 52 weeks Amplicor PCR Assay (Roche) 300 copies/ml 9.50 40.4
458 TBV 600 mg 32 73 9.50 60
Hou [22] 104 weeks Phase 3 randomised, double blind 147 TBV 600 mg 28 80 52 weeks Amplicor PCR Assay (Roche) 300 copies/ml 9.30 66.7
143 LAM 100 mg 29 75 9.70 37.8
ILSG [23] 52 weeks Randomised, partially double blind 82 LAM 100 mg 30 71 52 weeks Solution hybridising assay (Abbott) 1.6 pg/ml 2.04 60
69 IFNA 32 81 1.78 29.1
Lau [47] 72 weeks Phase 3 randomised, double blind 271 PegIFNA 32.5 79 48 weeks Amplicor PCR Assay (Roche) 400 copies/ml 9.90 25.1
272 LAM 100 mg 31.6 79 10.10 39.7
Leung [25] Minimum 52 weeks Phase 3 randomised, open label 33 ETV 0.5 mg 37 61 48 weeks Amplicor PCR Assay (Roche) 300 copies/ml 10.30 57.6
32 ADV 10 mg 32 66 9.88 18.8
Marcellin [26] 48 weeks Phase 3 randomised, double blind 176 TDF 300 mg 34 68 48 weeks Cobas Taq-Man PCR Assay (Roche) 169 copies/ml 8.64 76.1
90 ADV 10 mg 34 71 8.88 13.3
Ren [27] 48 weeks Randomised 21 LAM 100 mg 34 52 48 weeks PCR assay (company unspecified Unspecified 8.49 38
21 ETV 0.5 mg 31 57   8.52 71.4
TBVIG [29] 52 weeks Phase 2 randomised, double blind 19 LMV 100 mg 34 74 52 weeks Amplicor PCR Assay (Roche) 200 copies/ml N/R 31.6
22 TBV 600 mg 40 82   N/R 61.4
USLIG [30] 68 weeks Prospective, randomised, double blind 71 Placebo 38 80 52 weeks Unspecified Unspecified 5.70 15.9
    66 LAM 100 mg 40 86     10.20 44.4
  1. The systematic review identified 21 studies reporting hepatitis B e antigen (HBeAg)-positive patients; this table only shows the 14 studies included in the network meta-analysis. The remaining 7 studies did not report outcomes at 1 year and so were not included in the network meta-analysis. *Patient numbers for overall population provided, baseline viral load and hepatitis B virus (HBV) DNA reported as HBeAg-positive/HBeAg-negative, outcomes for HBeAg-positive patients only. ADV, adeforvir; ETV, entecavir; IFNA, interferon-alfa; LAM, lamivudine; LLOQ, lower level of quantification; NR, not reported; PegIFNA, pegylated interferon-alfa 2a; TBV, telbivudine; TDF, tenofovir.